Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and Bevacizumab
Status:
Recruiting
Trial end date:
2027-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to assess the overall survival of patients treated with the Xoft
Axxent eBx System and post-radiation adjuvant Bevacizumab for single-fraction IORT following
maximal neurosurgical resection of recurrent glioblastoma. A historical comparison will be
made to the results of the EBRT + Bevacizumab arm of RTOG 1205.